Skip to main content

Healthpeak Properties Receives Entitlements for an Additional 1.3 Million Square Feet of Development at the Vantage Campus in South San Francisco

Healthpeak Properties, Inc. (NYSE: PEAK) (“Healthpeak”), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced it has received approval of entitlements for Phases II and III of its purpose-built lab development campus, Vantage, in South San Francisco.

This press release features multimedia. View the full release here:

Rendering of Vantage Campus Phases II & III by Flad Architects (Graphic: Business Wire)

Rendering of Vantage Campus Phases II & III by Flad Architects (Graphic: Business Wire)

The newly awarded entitlements provide Healthpeak the ability to deliver an additional 1.3 million square feet of lab space, bringing the combined campus to approximately 1.7 million square feet upon full buildout. These entitlements represent double the allowable density compared to when Healthpeak originally acquired the land. The long-term nature of the entitlements offers flexibility to deliver the balance of the development in phases to align with market demand.

Strategically located in the heart of South San Francisco and at the doorstep of Genentech’s headquarters, the 20-acre purpose-built lab campus offers tenants a highly amenitized, world-class campus setting with access to multiple modes of transportation including direct access to the Rails-to-Trails pathway, which provides a pedestrian connection to downtown South San Francisco's restaurant and retail corridor, as well as the Caltrain station, which recently completed a multi-year renovation.

“Inspired by our success at The Cove and other nearby campuses, the Vantage master plan is a continuation of Healthpeak’s vision to create a world class campus that provides an inviting and collaborative setting for the nurturing of ideas, knowledge, and discoveries that shape the biotech industry,” said Scott Bohn, Healthpeak’s Chief Development Officer and Co-Head of Lab. “The future phases of Vantage provide Healthpeak a strategic development pipeline to meet the growth needs of our current and future tenants.” Mr. Bohn continued, “We’re appreciative of the collaborative and mutually beneficial relationship we have fostered with the City of South San Francisco over the past three decades and look forward to Vantage furthering South San Francisco’s position as a leading market for biotech innovation.”

In 2022, Healthpeak commenced construction on Phase I of the Vantage campus, consisting of 343,000 rental square feet across two buildings, as well as a 40,000 square foot amenity building featuring multiple dining options, conferencing space, and a fitness center. Phase I is currently 52% leased to Astellas Pharma, which took initial occupancy of its space in December 2023.

For additional information on the campus, please visit the Vantage website at


Healthpeak Properties, Inc. is a fully integrated real estate investment trust (REIT) and S&P 500 company. Healthpeak owns, operates, and develops high-quality real estate for healthcare discovery and delivery. For more information regarding Healthpeak, visit


Statements in this release that are not historical factual statements are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include those regarding the development of Vantage. All forward-looking statements are made as of the date hereof, are not guarantees of future performance and are subject to known and unknown risks, uncertainties, assumptions and other factors — many of which are out of Healthpeak's and its management's control and difficult to forecast — that could cause actual results to differ materially from those set forth in or implied by such forward-looking statements. These risks and uncertainties include but are not limited to: Healthpeak's ability to commence and complete the development, or portions thereof, to align with market demand; the risk that Healthpeak may not be able to achieve the benefits of the development within expected timeframes or at all, or within expected cost projections; and other risks and uncertainties described from time to time in Healthpeak's Securities and Exchange Commission filings. You should not place undue reliance on any forward-looking statements. Healthpeak assumes no, and hereby disclaims any, obligation to update any forward-looking statements as a result of new information or new or future developments, except as otherwise required by law.


Andrew Johns, CFA

Senior Vice President – Investor Relations


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.